Moshe Talpaz 1, Jean-Jacques Kiladjian 2 – Received: 14 February 2020 / Revised: 15 June 2020 / Accepted: 25 June 2020 © The Author(s) 2020. This article is published with open access Abstract Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of […]
Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis
The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]
